Tag: Revive Therapeutics Ltd.

August 26, 2020

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19
May 13, 2020

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

Revive Therapeutics is pleased to provide a corporate update on its pharmaceutical programs for Bucillamine in the treatment of the...
April 29, 2020

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

Revive Therapeutics is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program.
April 23, 2020

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

Revive Therapeutics (CSE:RVV) has received positive feedback from the U.S. FDA in response to the company’s pre-IND meeting that was...
April 21, 2020

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison

Revive Therapeutics (CSE:RVV) has entered into a SRPA with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery...
April 17, 2020

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

Revive Therapeutics (CSE:RVV) has engaged Complete Phytochemical Solutions to advance the Company’s research and development initiatives of psilocybin-based products for...
April 15, 2020

Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

Revive Therapeutics (CSE:RVV) has issued an additional 16,400,000 units at a price of $0.05 per Unit for gross proceeds of...